For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
IL-18BP, also known as IL18 BPa, IL-18 BPa, IL18BP, IL18BPa, and interleukin 18 binding protein, is a 20 kDa protein constitutively expressed and secreted from mononuclear cells. IL-18BPa contains one immunoglobulin (Ig)-like C2-type domain that has been shown to be essential to the binding and neutralizing properties of the binding protein. IL18BP is known as an inhibitor of the proinflammatory cytokine, IL-18. The production and secretion of IL-18BP is stimulated by IFNγ. IL-18BP binds to IL-18 to prevent the binding of IL-18 to its receptor and to inhibit IL-18-induced IFNγ production, resulting in reduced TH1 immune responses. An elevated level of this protein is detected in the intestinal tissues of patients with Crohn's disease, hematological malignancies, inflammatory diseases, and autoimmune disorders.
|Assay Target Class||Cytokine|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.